NATCO PHARMA LTD.
Long

Natco, the painkiller in a savvy Investors portfolio

Natco is a buy on close above 1205 as it signals that it has overcome the 0.618 fibonacci retracement level and price above the 2021 highs forming a cup pattern... however the support line from 2023 could act as a resistance. The 1st target is 1876

However, all that was technical. Fundamentally, Natco is all poised to deliver its highest profits due to the maximum exclusive selling rights of gRevlimid and the USD being where it is, we have a nice little tailwind going for us. The only issue is the thin patience of the investor community as Natco has a habit of being the last few to declare results. Q1 of FY25_26 would br declared in the fag end of May but fireworks should be starting earlier than than. I say its good to be early than late, after all who knows where the bottom is.

Disclaimer